期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性乙型肝炎患者拉米夫定和恩替卡韦基因型耐药突变特征分析 被引量：6

Characterization of resistant mutants genotypes of Lamivudine and Entecavir in patients with chronic hepatitis B
下载PDF
导出
摘要 目的分析慢性乙型肝炎患者拉米夫定和恩替卡韦基因型耐药突变特征。方法对我院180例拉米夫定(LAM)和120例恩替卡韦(ETV)治疗的慢性乙型肝炎患者进行耐药基因分析,并将检测耐药基因突变的结果进行统计分析。结果 LAM耐药突变率为60.6%(109/180),常见耐药位点主要有rt 180Ml+rt 204V、rt 204I+rt 207I,变异频率分别为32.1%(35/109)和22.9%(25/109)。ETV耐药突变率为58.3%(70/120),常见耐药位点主要有rt 184L+rt180M+rt 204V,变异频率为80.0%(56/70)。结论LAM和ETV存在rt 204V共同耐药位点,但是不会在临床过程中同时显现HBV-DNA阳性,当LAM耐药后,可用ETV继续治疗。 Objective To analyze the characteristics of resistant mutant genotypes of Lamivudine（LAM） and Entecavir（ENT） in patients with chronic hepatitis B.Methods One hundred and eighty patients with chronic hepatitis B who were treated with LAM and 120 treated with ENT were involved in this study.The resistant gene was analyzed,and the resistant mutant genotypes were detected and conducted by statistics.Results The resistant mutant rates of LAM was 60.6%（109/180）,and its common resistant loci was rt 180Ml＋rt 204V and rt 204I＋rt 207I with mutation frequency 32.1%（35/109） and 22.9%（25/109） respectively.The resistant mutant rates of ETV was 58.3%（70/120）,and its common resistant loci was rt 184L＋ rt 180M＋ rt 204V with mutation frequency 80.0%（56/70）.Conclusion There is a common resistance loci rt 204V for both LAM and ETV,but it is not possible for the presence of positive HBV-DNA in both LAM and ETV.ETV can be used to treat the patients with resistant mutant of LAM.
作者 王珠 王武
机构地区 海南省儋州市第一人民医院内科
出处 《中国医药导报》 CAS 2012年第11期97-98,共2页 China Medical Herald
关键词 慢性乙型肝炎 拉米夫定 恩替卡韦 耐药突变 Chronic Hepatitis B Lamivudine Entecavir Resistant mutant
分类号 R575.2 [医药卫生—消化系统]
  • 相关文献

参考文献5

二级参考文献15

  • 1徐东平,李进,张玲霞.恩替卡韦治疗慢性乙型肝炎的研究进展[J].中华医学杂志,2006,86(28):2014-2016. 被引量：52
  • 2Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 1998, 27: 1670-1677.
  • 3Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother, 2006, 50: 3867-3874.
  • 4Qi x, Snow A, Thibault V, et al. Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. J Hepatol, 2004, 40(suppl 1): 20-21.
  • 5Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 2006, 354: 1807- 1812.
  • 6Tenney D J, Rose RE, Baldick C J, et al. Two-year assessment of entecavir resistance in Larnivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother, 2007, 51: 902-911.
  • 7Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology, 2005, 129: 528- 536.
  • 8Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46: 254-265.
  • 9Borroto-Esoda K, Miller MD, Arterbttrn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol, 2007, 47: 492-498.
  • 10Ciancio A, Smedile A, Rizzetto M, et al. Identification ofHBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology, 2004, 39: 64-73.

共引文献14047

同被引文献66

  • 1赵鸿,张跃新,陈新月,王磊,唐小平,斯崇文.国产阿德福韦酯片治疗拉米夫定失效HBeAg阳性慢性乙型肝炎患者的临床研究[J].中华内科杂志,2007,46(4):294-297. 被引量：8
  • 2朱锦宏.阿德福韦酯联合拉米夫定治疗慢性乙肝的疗效研究[J].药物与临床,2012,50(12):73-75.
  • 3Adams LA.Biomarkers of liver fibrosis[J].J Gastroen Hepatol,2011,26 (5):802-809.
  • 4Nan XP,Zhang Y,Yu HT,et al.Circulating CD4+CD25+high regulatory T cells and expression of PD-1 and BTLA on CD4+Tcells in patients with chronic hepatitis B virus infection[J].Viral Immunol,2010,23 (1):63-70.
  • 5Li X,Chen Y,Ma Z,et al.Effect of regulatory T cells and adherent cells on the expansion of HbcAg-specific CD8+T cells in patients with chronic hepatitis B virus infection[J].Cell Immunol,2010,264 (1):42-46.
  • 6Zhao P,Wang C,Huang LL,et al.Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B[J].Antiviral Research,2012,96(2):100-104.
  • 7Schiff ER,Lee SS,Chao YC,et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J].Clini Gastroen Hepatol,2011,9 (3):274-276.
  • 8Nan XP, Zhang Y, Yu HT, et al. Circulating CD4^+ CD25^+ high regulatory T cells and expression of PD - 1 and BTLA on CD4 ^+ Tcells in patients with chronic hepatitis B virus infection [ J ]. Viral Immunol, 2010, 23(1): 63-70.
  • 9Zhao P, Wang C, Huang LL, et al. Comparison of rescue strategies in lamivudine -resistant patients with chronic hepatitis B[ J]. An- tiviral research, 2012, 96(2): 100- 104.
  • 10Li X, Chen Y, Ma Z, et al. Effect of regulatory T cells and adher- ent ceils on the expansion of HbcAg - specific CD8^ + T cells in pa- tients with chronic hepatitis B virus infection [ J ]. Cell Immunol, 2010, 264(1) : 42-46.

引证文献6

二级引证文献15

中国医药导报
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部